Phase I Trial of Cabozantinib (XL184) for Advanced Solid Tumors in Persons With HIV Infection
Phase of Trial: Phase I
Latest Information Update: 06 Dec 2017
At a glance
- Drugs Cabozantinib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 01 Dec 2017 Planned primary completion date changed from 1 Apr 2017 to 31 Dec 2018.
- 10 Jun 2017 Biomarkers information updated
- 01 Jun 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.